Terry Rosen, Arcus CEO
Gilead goes all in on its Arcus alliance, paying $725M cash for rights to a slate of cancer drugs. And there's no room for failure
Gilead is going all in — hook, line and sinker — on its oncology alliance with Arcus. And they are going for broke.
The big biotech unveiled …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
